Erkennen und Umgang von/mit Medikamentennebenwirkungen
Publisher
Springer Vienna
Reference19 articles.
1. Buttgereit F, DA Silva JA, Boers M et al (2002) Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: Current questions and tentative answers in rheumatology. Ann Rheum Dis 61: 718–722
2. Buttgereit F, Doering G, Schaeffler A et al (2008) Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): A double-blind, randomised controlled trial. Lancet 371: 205–214
3. Buttgereit F, Saag KG, Cutolo M et al (2005) The molecular basis for the effectiveness, toxicity and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis. Scand J Rheumatol 34: 14–21
4. Buttgereit F, Straub RH, Wehling M et al (2004) Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 50: 3408–3417
5. Da Silva J A P, Jacobs J W G, Kirwan J R et al (2006) Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 65: 285–293